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a b s t r a c t 
Arrhythmogenic cardiomyopathy (ACM) is a familial disease, with approximately 60% of patients display- 
ing a pathogenic variant. The majority of genes linked to ACM code for components of the desmosome: 
plakophilin-2 ( PKP2 ), desmoglein-2 ( DSG2 ) and desmocollin-2 ( DSC2 ), plakoglobin ( JUP ) and desmoplakin 
( DSP ). Genetic variants involving the desmosomes are known to cause dysfunction of cell-to-cell adhe- 
sions and intercellular gap junctions. In turn, this may result in failure to mechanically hold together 
the cardiomyocytes, fibrofatty myocardial replacement, cardiac conduction delay and ventricular arrhyth- 
mias. It is becoming clearer that pathogenic variants in desmosomal genes such as PKP2 are not only 
responsible for a mechanical dysfunction of the intercalated disc (ID), but are also the cause of various 
pro-arrhythmic mechanisms. In this review, we discuss in detail the different molecular interactions as- 
sociated with desmosomal pathogenic variants, and their contribution to various ACM phenotypes. 
© 2020 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
Introduction 
Arrhythmogenic cardiomyopathy (ACM) is a progressive herita- 
ble cardiac condition encompassing a broad spectrum of pheno- 
types. Arrhythmogenic right ventricular cardiomyopathy (ARVC) is 
the most classical form of ACM. The disease is one of the lead- 
ing causes of ventricular arrhythmias and may lead to sudden car- 
diac death (SCD) in young, athletic people. SCD can occur as the 
first disease manifestation even before structural changes mani- 
fest in up to 11% of index cases [1] . The natural history of ACM 
has four phases: an early concealed phase , during which struc- 
tural abnormalities are undetectable, but can put the patients, es- 
pecially athletes who practice strenuous exercise, at an increased 
risk of SCD [2] . The second phase is an overt electrical disorder 
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with ECG abnormalities such as inverted T-waves, typically in right 
precordial leads, and arrhythmias with left bundle branch block 
(LBBB) morphology, and hence arising from the right ventricle 
(RV). Structural changes are mostly confined to specific RV regions 
and are best detected by cardiac magnetic resonance (MRI) or by 
strain evaluation in echocardiography. The following phase typi- 
cally shows an extension of the RV disease with a progressive loss 
of healthy myocardium and fibrofatty replacement [3] leading to a 
RV global dysfunction. Finally, the disease progresses into end-stage 
heart failure with biventricular involvement. 
There are also non-classical forms of ACM showing atypical 
clinical presentation, which have only been reported in recent 
years. One is a left ventricle (LV)-dominant disease (ALVC) with 
limited or absent RV involvement, and another is a so-called biven- 
tricular form, in which there is an early involvement of both ven- 
tricles. Although the natural history of ALVC awaits further elu- 
cidation, its clinical profile is clearly distinct from ARVC. In this 
disease, arrhythmias typically have a right bundle branch block 
(RBBB) morphology and LV impairment/dilation without RV in- 
volvement can be detected in up to 30% of cases [4] . The biven- 
tricular form, on the other hand, shows parallel involvement of 
both ventricles starting in the early stages. Clinically, it may range 
from a mild disease with localized structural abnormalities to 
an advanced disease with biventricular dilation and/or systolic 
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Fig. 1. The intercalated Disc . 
The ID is composed of three structures: desmosomes, adherens junctions and gap junctions. These regulate respectively the mechanical and electrical continuity of cardiac 
myocytes, with desmosomes being involved in a crosstalk between adherens and gap junctions [2] . 
impairment. The electrical phenotype suggests ventricular arrhyth- 
mias of biventricular origin [5] . 
Genetic background and clinical phenotypes 
ACM is known to be a familial disease, with approximately 
60% of patients carrying a genetic pathogenic variant. It is com- 
monly considered as a disease of the intercalated disc (ID), the 
structure in charge of the end-to-end contact of cardiac my- 
ocytes and implied in mechanical and electrical coupling. ( Fig. 1 ) 
The majority of genes linked to ACM code for components of 
the desmosomes: plakophilin-2 ( PKP2 ), desmoglein-2 ( DSG2 ) and 
desmocollin-2 ( DSC2 ), plakoglobin ( JUP ) and desmoplakin ( DSP ). In 
addition, there are non-desmosomal genes such as the transmem- 
brane protein 43 ( TMEM43 ), desmin ( DES ), phospholamban ( PLB ), 
N-cadherin ( CDH2 ), sodium voltage-gated channel alpha subunit 5 
( SCN5A) , titin ( TTN ) and transforming growth factor 3 beta ( TGF3 β) 
[6] which have also been shown to cause ACM. While most pheno- 
types are associated with autosomal dominant transmission, there 
are two forms that are autosomal recessive. A homozygous mu- 
tation in plakoglobin causes Naxos disease, which presents with 
both cardiac and cutaneous involvement and onset of symptoms 
starting in childhood. Carvajal Syndrome is another autosomal re- 
cessive form, caused by mutations in DSP and also has a cardio- 
cutaneous phenotype, characterized by woolly hair, palmoplantar 
keratoderma and heart disease [3] . Typical surface ECG abnormali- 
ties in ARVC include epsilon waves, QRS prolongation and inverted 
T waves in the right precordial leads (V1-V3), and arrhythmias of 
RV origin. Even though structural abnormalities in the RV are the 
most dominant, LV involvement occurs with disease progression 
[2] . Pathogenic variants in PKP2 are usually associated with the 
classical form of the RV disease [7] . There may be LV involvement 
in late-stage PKP2 disease, but this is much less prominent than 
what can be seen in other genetic forms such as the ones linked 
to DSG2 or DSC2 , which show prominent LV involvement even dur- 
ing early disease. On the other hand, DSP pathogenic variants have 
been associated with ALVC. In this case, clinical features include in- 
ferolateral T wave inversions, arrhythmias of LV origin and promi- 
nent late gadolinium enhancement (LGE) of the LV myocardium. 
Of note, cases with multiple heterozygous mutations tend to have 
a more severe phenotype than cases with a single mutation. 
Genetic mutations involving the desmosomes are known to 
cause dysfunction of cell-to-cell adhesions and intercellular gap 
junctions. These result in failure to mechanically hold together the 
cardiomyocytes, fibrofatty myocardial replacement, cardiac conduc- 
tion delay and ventricular arrhythmias. In this review, we discuss 
the different molecular interactions associated to desmosomal mu- 
tations, which contribute to various ACM phenotypes. 
Desmosomal mutations and molecular interactions: 
mechanisms of arrhythmogenesis 
The central role of PKP2 
The majority of genotype-positive cases of ARVC are due 
to PKP2 pathogenic variants. PKP2 is mainly known for its 
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Fig. 2. The pivotal role of PKP2 . 
The malfunction of the PKP2 protein causes a chain of events, which may lead to arrhythmias through various pathways. • Reduced PKP2 determines an altered Na v1.5 
interaction with ancillary proteins such as Ankyrin G, which is required for Na v1.5 trafficking [13] . • PKP2 -cKO cardiomyocytes present an increase in amplitude, prolonged 
duration and increase in time to peak of calcium transients and a prolonged action potential duration. • Ca 2 + homeostasis imbalance coincided with a Cx43-dependent 
increase in RV membrane permeability. Ca 2 + overload seems to be facilitated by increased availability of Cx43 hemichannels in the sarcolemma, increasing its arrhythmogenic 
potential. 
mechanical functions: It provides the lateral stabilizing force, 
which facilitates cell-to-cell adhesion together with the desmo- 
somal intermediate filament [2] . Nevertheless, this definition has 
been revised in recent years in order to include a more pleiotropic 
role of this protein: on top of its role in cellular adhesion, it is re- 
sponsible for the regulation of multiple molecular pathways as a 
part of the connexome complex [8] . The malfunction of the PKP2 
protein causes a chain of events that may lead to the disruption of 
intracellular signaling, of electrophysiology and of the cardiac tran- 
scription program [9] . 
It has been suggested that arrhythmias are a consequence of 
reentry mechanisms around anatomical obstacles due to patchy 
cardiomyocyte loss and fibrofatty infiltration. However, while this 
certainly cannot be excluded, it is now clear that life-threatening 
ventricular arrhythmias often occur in the early phase of the dis- 
ease, before any overt structural damage can be found [5] . Studies 
aimed at discovering the relation between a mutant PKP2 and ar- 
rhythmias proved that PKP2 is essential to maintain gap junction 
integrity [10] . While the mechanisms underlying this arrhythmo- 
genicity still remain unclear, there is now evidence that various 
pathways are involved ( Fig. 2 ). 
PKP2 and the sodium channel complex 
One of the first molecular interactions described in ACM was 
the one between PKP2 and the voltage gated sodium channel (Nav 
1.5): they are both located within the cardiac ID, and rat cardiomy- 
ocytes silenced for Pkp2 showed reduced Nav 1.5 levels and sodium 
current density [11] . Following this path, Cerrone et al. showed in a 
murine model of Pkp2 haploinsufficiency that sodium current am- 
plitude was decreased, and the steady-state inactivation had a neg- 
ative shift. Furthermore, macropatch recordings of cardiomyocytes 
haploinsufficient for Pkp2 showed a selectively decreased sodium 
current in the region of the ID. The reduced abundance of Pkp2 
in this model was shown to correlate with increased separation 
between the microtubule plus-end tracking protein EB-1 and sites 
rich with N-cadherin [12] . This led to the hypothesis that Pkp2 is 
part of a molecular complex that seizes the microtubules plus-end 
at the ID and allows passage of its contents. While this evidence 
alone does not explain why there is a change of gating and ki- 
netics of the sodium current in the model, it is possible that re- 
duced Pkp2 determines an altered Na v1.5 interaction with ancillary 
proteins such as Ankyrin G, which is required for Na v1.5 traffick- 
ing [13] . Interestingly, a reduction of Nav 1.5 expression has also 
been detected in human tissue samples (from the RV free wall 
postmortem or from RV septal biopsies) from ARVC patients with 
PKP2 variants, as Noorman et al. showed substantial disturbance of 
the immunoreactive signals for Nav 1.5, Cx43 and PKG [14] . Simi- 
lar results were shown in a cohort of patients with heterozygous 
DSP variants by Gomes et al., where in two tissue samples, Nav 
1.5 was localized away from the ID. Furthermore, on electrophysi- 
ological mapping there were conduction delays showed by shorter 
coupling intervals and proven by activation delay curves, especially 
in the RVOT [15] . 
However, it is unlikely that sodium channel dysfunction is the 
only mechanism for the occurrence of spontaneous arrhythmias, 
but rather it may contribute to arrhythmogenesis in the early 
stages of ARVC through additional electrophysiological factors. 
Pkp2: Ca 2 + handling and Cx43 interaction 
Dysfunctional calcium handling has been proposed as a mech- 
anism for arrhythmogenesis in ACM more recently. Cerrone et al. 
[16] generated a cardiac restricted, tamoxifen-activated conditional 
Pkp2 knock-out mouse model (Pkp2-cKO), which manifests a phe- 
notype of progressive ACM starting with RV predominance and 
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subsequently showing biventricular involvement. Transcriptome 
analysis showed that the calcium signaling pathway was affected, 
generating lower transcripts and lower protein levels of Ank2 (cod- 
ing for ankyrin-B), Ryr2 (coding for the cardiac ryanodine recep- 
tor), Trdn (coding for triadin) and Cacna1c (coding for Ca V 1.2). 
Functional studies showed the Pkp2-cKO cardiomyocytes present 
a surge in amplitude, prolonged duration and increase in time to 
peak of calcium transients and a prolonged action potential dura- 
tion. The loss of Pkp2 also facilitated early and delayed afterde- 
polarizations, likely sufficient to predispose to ventricular arrhyth- 
mias. Interestingly, all these pro-arrhythmic alterations in the Ca 2 + 
handling pathways manifested since the early disease stages, be- 
fore the mouse model presented overt structural cardiomyopathy. 
Further studies [17] in this model showed that loss of Pkp2 causes 
an accumulation of Ca 2 + in three intracellular compartments: the 
junctional sarcoplasmic reticulum, the cytoplasm and the mito- 
chondria. Moreover, Ca 2 + homeostasis imbalance was found to 
be sensitive to reduced expression of Cx43 and coincided with a 
Cx43-dependent increase in RV membrane permeability. Possibly, 
loss of desmosomal integrity causes a loss of stability of the neigh- 
boring gap junctions with consequent increase of orphan Cx43 
hemichannels in the perinexus. 
Reduced expression of Cx43 at the ID has also been shown his- 
tologically in ACM patients: Kaplan et al. reported that a 7-year-old 
patient with genotypically confirmed Naxos disease, but no overt 
structural heart disease (neither at echography, nor histologically), 
indeed showed significantly reduced myocardial Cx43 expression 
at the ID [18] . Furthermore, similar results were shown by Gomes 
et al. who detected marked downregulation of Cx43 at the ID in 
myocardial biopsies from three patients carrier of DSP heterozy- 
gous variants in the absence of overt structural disease [15] . It is 
important to note that Cx43 occupies both the ID and the mito- 
chondrial membrane and recent studies have shown how mito- 
chondrial Cx43 hemichannels participate in mitochondrial Ca 2 + en- 
try [19] . Under pathologic conditions, mitochondrial Ca 2 + overload 
causes reactive oxygen species (ROS) production, which interferes 
with the sarcoplasmic reticulum Ca 2 + cycling through oxidative 
stress induction and elevates the cytosolic Ca 2 + levels [20] , which 
in turn activates several arrhythmogenic pathways and causes trig- 
gered activity in the heart. In the Pkp2 -cKO mouse, intracellular 
Ca 2 + overload seems to be facilitated by increased availability of 
Cx43 hemichannels in the sarcolemma [17] . A recent work from 
our group [21] postulated that a surge in mitochondrial perme- 
ability, via mitochondrial Cx43 (MtCx43) channels, would cause 
mitochondrial Ca 2 + overload as a consequence of decreased Pkp2 
expression because of an excessive entry of Ca 2 + into the mito- 
chondria. While further studies are certainly needed, this draws a 
phenotypical picture in which the loss of Pkp2 not only creates a 
RV-predominant cardiomyopathy, but also possibly results in an ar- 
rhythmogenic substrate, mostly in the RV ventricle, that precedes 
the cardiomyopathy ( Fig. 3 ). 
The role of DSG2 
A Dsg2 mutant model developed by Pilichou et al. [22] showed 
an expansion of the ID in proximity of the area composita, which 
coincided with slowing of conduction, and a consequent reduction 
in action potential upstroke velocity, stemming from a decrease in 
the cardiac I Na density. The mutated N271S residue, which is po- 
sitioned between the second and third extracellular cadherin do- 
mains of Dsg2 is known to be of utmost importance for coordina- 
tion of Ca 2 + binding, which on the other hand is essential to the 
adhesive function of junctional cadherins. Two possible pathogenic 
mechanisms have been proposed for this model: either the Na + 
channel complex is weakened by the widening of the ID caused by 
the N271S variant, or the latter causes a conformational change, 
which challenges the natural interaction between the desmoso- 
mal and the Na + channel complex regardless of intercellular space 
widening [23] . Similar to the Pkp2 mechanism proposed by the 
Delmar group, using the above mentioned model, Rizzo et al. also 
provided evidence that Dsg2 and Nav1.5 interact in vivo, which 
leads to believe that the presence of a molecular mechanism re- 
sponsible for conduction slowing and arrhythmia in ARVC prior 
to overt changes, is indeed possible [24] . This was also confirmed 
more recently, when El-Battrawy et al. [25] reported how iPSCs- 
derived cardiomyocytes from an ARVC patient carrying a Dsg2 vari- 
ant, presented with multiple ion channel dysfunctions and arrhyth- 
mia events, reduced action potential amplitude and V max and a re- 
duced I Na . 
The role of DSP 
A murine model haploinsufficient for DSP showed reduced ex- 
pression and remodeling of Cx43 at the ID, preceding overt his- 
tological abnormalities [15] . The downregulation of Cx43 preced- 
ing fibrofatty replacement has further been confirmed in a murine 
model of cardiac-restricted loss of Dsp mice [26] . The Dsp -cKO 
hearts revealed electrical wave front propagation defects that are 
associated with loss of Cx43. A dose-dependent assessment of Dsp 
loss aimed at confirming that Cx43 loss was a primary conse- 
quence of loss of Dsp , revealed a dose-dependent knockdown of 
total and phosphorylated Cx43 levels, independent of any molecu- 
lar dissociation of the desmosomal as well as the fascia adherens 
junction complex. This was shown by normal levels of Pkp2 and 
N Cadherin in the neonatal cardiomyocytes with Dsp knockdown. 
This loss caused electrical abnormalities prior to the mechanical 
junction complex dissociation and independently from any histo- 
logical fibrofatty manifestations [26] . Furthermore, DSP is a plakin 
responsible for tethering intermediate filaments (IF) to desmo- 
somes, and while it does not associate to microtubules (MT) di- 
rectly, it has been shown to mediate MT reorganization. Patel et al. 
[27] have shown that DSP interaction with the end-binding-1 pro- 
tein (EB1) of MT (a protein which regulates MT dynamics) is criti- 
cal to DSP regulation of MTs dynamics. The disturbance of this in- 
teraction causes mis-localization and malfunction of Cx43: DSP or 
EB1 knockdown or mutations impeding the binding of DSP-EB1 or 
the membrane localization of this interaction, caused an impaired 
membrane localization of Cx43 and gap junction function, proba- 
bly due to either a direct association with EB1 causing disruption 
or by a mis-localization of DSP and thus EB1. 
Desmosomal mutations and molecular interactions: fibrofatty 
infiltration and inflammation 
In ACM, part of the myocardium (preferentially the RV) is re- 
placed by fibrotic tissue, which is the histological hallmark of dis- 
ease. These changes may be accompanied by inflammatory infil- 
trates, detected in samples from heart autopsies in up to 60–88% of 
cases [28] . The mechanisms underlying these phenomena are still 
under investigation and not completely understood. 
PKP2 and fibrosis 
In the presence of cardiac muscle injury, fibroblasts are ac- 
tivated and start differentiating into myofibroblasts, thus initiat- 
ing the profibrotic process. However, the mechanisms that causes 
the formation of fibrotic tissue in the myocardium are still not 
well known. In the setting of ACM, it has been hypothesized that 
PKP2 deficiency could facilitate fibrosis through the TGF β-signaling 
pathway [29] . Recently non-canonical TGF β-signaling pathways 
have been recognized, the most remarkable being the activation 
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Fig. 3. PKP2 – RYR2 arrhythmogenesis . 
In the context of the PKP2cko model, sarcoplasmic reticulum (SR) Ca 2 + release can be modulated both by RyR2 phosphorylation (specifically the phosphorylation on T2809) 
and increased abundance of connexin43 hemichannels. These pathways facilitate early and delayed after depolarizations, and hence, arrhythmogenesis. 
of mitogen-activated protein kinase (MAPK) signaling and genera- 
tion of ROS [30] . Specifically, this relates to the TGF- β1 P38 MAPK 
signaling cascade, which elicits the activation of a transcriptional 
program that is profibrotic. The loss of PKP2 triggers an increase 
in TGF β1 expression, which in turn activates the p38 MAPK cas- 
cade, a known supporter of the TGF β-induced collagen synthesis. 
The loss of PKP2 also results in a disruption of the area composita 
formation with a loss of DSP incorporation at cell-to-cell junctions, 
with an increased solubility and degradation of DSP [30] . Even in 
the presence of a PKP2 deficiency, the reinstatement of DSP ex- 
pression is sufficient to rescue the increased expression of TGF- 
β1 mRNA and its consequent downstream phosphorylation of p38 
MAPK induced by the PKP2 KD. This points to an interplay be- 
tween the two proteins. Interestingly, neighboring PKP2 positive 
cells show p38-MAPK activation as well, suggesting both the pres- 
ence of a cell-to-cell interplay between PKP2 positive and nega- 
tive cells and of a paracrine pathway recruiting of pro-fibrotic pro- 
cesses. 
Adenosine may also play a role as a pro-fibrotic messenger in 
case of PKP2 deficiency. It has been shown in previous studies that 
when adenosine binds to the adenosine 2A receptor (A2AR), this 
results in an increased collagen deposition in tissues such as skin, 
lung and liver. In the heart tissue, ATP is swiftly converted into 
adenosine, which binds to its G-coupled protein receptor (A2AR) 
[31] . Cerrone et al. explored the role of adenosine in Pkp2 defi- 
cient mouse hearts and showed that in Pkp2 deficient cells, ATP 
release was significantly increased, however upon silencing of both 
Pkp2 and Cx43, the release of ATP was significantly reduced, which 
suggests the presence of Cx43 hemichannels as conduit for ATP 
in Pkp2 deficient cells [32] . Furthermore, istradefylline (a specific 
A2AR antagonist) partially interrupted the cardiomyopathic phe- 
notype and reduced collagen deposition, confirming the role of 
adenosine in the unfolding of ACM. 
PKP2 and adipogenesis 
The Hippo pathway regulates organ size and cell proliferation, 
survival and differentiation. In the canonical Hippo cascade, it 
suppresses the YAP pathway, which inhibits the canonical Wnt- 
pathway through the interaction with catenin β1. Through the in- 
hibitory Hippo kinase activity, the catenin β1 translocation to the 
nucleus is suppressed. In PKP2 depleted cells this mechanism is 
supposed to be brought about by the fact that PKP2 deficiency 
causes reduction in levels and partial inactivation of PKC α, which 
is required to inactivate NF2. The activation of NF2 then correlates 
with the cascade phosphorylation of the Hippo kinases, which in 
turn prevent the nuclear translocation of βcatenin and thus the 
activation of the Wnt-pathway [35] . 
Another candidate for the pro-adipogenic signaling in ACM are 
PPARs (peroxisome proliferator-activated receptor), in particular 
PPAR γ , a nuclear receptor responsible for the adipogenesis and 
the differentiation of pre-adipocytes to adipocytes: in a study con- 
ducted by Kim et al. [33] hiPSC-CMs mutant for PKP2 were shown 
to increase PPAR γ expression, decrease catenin β1 activity and pro- 
mote lipogenesis. 
Desmosomal variants and fibrofatty infiltration 
Fibrofatty infiltration was not only shown in the PKP2 related 
form. The activation of the Hippo and Wnt-pathways have been 
proposed as a possible mechanism stimulating fibro-adipogenesis 
in the setting of desmosomal pathogenic variants [13] . The part 
played by the Wnt-signaling pathway in fibro-adipogenesis has 
been described initially for JUP . Also known as γ -catenin or PKG 
(plakoglobin), it shares functional and structural properties with 
β-catenin, which on the other hand is an activator of the Wnt- 
signaling pathway via activation of the T cell \ lymphoid-enhancing 
binding transcription factors. Since one of the hallmark features 
of ACM is fibro-adipogenesis, and suppression of the canonical 
Wnt/ β-catenin pathway is a known cause of this, it is thought 
that nuclear translocation of JUP can inactivate this pathway by 
competing with β-catenin. This hypothesis was tested initially by 
Garcia-Gras et al. [34] who showed that the suppression of DSP 
in a cardiac cell line (HL-1 cells) and subsequently in Dsp de- 
ficient mice led to nuclear localization of JUP , its competition 
with β-catenin, suppression of the Wnt/ β-catenin signaling path- 
way with consequent enhanced myocyte apoptosis, excess fibro- 
adipogenesis, myocardial dysfunction and ventricular tachycardia. 
Noorman and colleagues reported decreased ID PKG signal by im- 
munofluorescence in human heart ACM samples, independently 
from the genetic background [14] . Similar results were shown by 
Asimaki et al. in a model of neonatal rat cardiomyocytes with the 
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Fig. 4. Suppression of the Wnt Pathway as a cause for adipogenesis . 
Suppression of the canonical Wnt \ β-catenin pathway can lead to enhanced adipogenesis through two possible pathways. • Nuclear translocation of JUP, a lso known as γ - 
catenin, can inactivate this pathway by competing with β-catenin. • PKP2 deficiency causes reduction in levels and partial inactivation of PKC α, which then cannot inactivate 
NF2: this leads to a cascade phosphorylation of the Hippo kinases, which in turn prevent the nuclear translocation of βcatenin and thus the activation of the Wnt-pathway 
[9] . 
expression of a truncated version of Jup (2057del2). Jup was shown 
to be reduced at the cell-to-cell junctions and abundant in the cell 
nuclei [35] . Interestingly, the authors also found that the mutant 
Jup cardiomyocytes showed decreased amounts of SAP97, a regu- 
lator protein of Nav 1.5 and Kir2.1, which are the major protein 
subunits in charge of I Na and I k1 currents, respectively. This sug- 
gests that altered trafficking of ion channel proteins to the cell 
membrane may be the cause of the remodeling of the action po- 
tential and of the decreased I na and I k1 currents. In addition, mu- 
tant Jup sensitized the cells to the secretion of multiple cytokines 
such as IL-6 and TNF, suggesting a possible link between desmo- 
somal dysfunction and the known inflammatory response seen in 
ACM. Furthermore, the SB216763 (SB2) molecule could rescue dis- 
ease features caused by the expression of Jup 2057del2, such as 
decreased expression of Cx43 or action potential remodeling [35] . 
This molecule is an inhibitor of GSK3 β , and increases canonical 
Wnt-signaling [36] . Recent studies have shown a dichotomic role 
of GSK3 β: under physiological conditions inhibition of GSK3 β em- 
powers Wnt-signaling and disturbs cardiac homeostasis causing 
myocardial fibrosis, while inhibition of GSK3 β in pathologic condi- 
tions such as myocardial infarction, results in cardioprotection and 
downregulation of myocardial fibrosis [37] . On the basis of this, 
Judge and colleagues have shown how GSK3 β localized abnormally 
at the myocyte junction in two different mouse models of desmo- 
somal dysfunction ( Dsg2 mut/mut mutant mice and JUP2157del2 mu- 
tant mice), at variance with their controls [38] . These models, 
which were created respectively with an inducible knock-in mu- 
tation and a transgenic overexpression of JUP2157del2 cDNA under 
the control of the cardiac-specific mouse α-myosin heavy chain 
( αMHC) promoter, present biventricular fibrosis and focal inflam- 
mation, features of the clinical spectrum of ACM. They also show 
molecular changes (abnormal plakoglobin (PLK) and connexin43 
(Cx43) signal at myocyte junctions), when compared to controls. 
Interestingly, this phenotype was markedly improved by admin- 
istration of the SB2 molecule mentioned above. Furthermore, the 
group found the same pattern of abnormal GSK3 β distribution at 
the ID in NRVM expressing mutant forms of Jup (JUP2157del2) or 
Pkp2 (1851del123) and in paraffin-embedded cardiac tissue sec- 
tions from ACM patients with known desmosomal gene pathogenic 
variants. Finally, the pathogenic role of GSK3 β was further con- 
firmed by a Dsg2 mutant mice bred in with a strain of mice 
with a knock-in mutation in the murine GSK3 β gene (constitu- 
tively activating GSK3 β), which demonstrated an increase in car- 
diac dysfunction and myocardial fibrosis. Several limitations have 
to be taken into account when considering these murine mod- 
els: the Dsg2 model is not cardiac specific and the possibility of 
the abnormalities being observed due to disruption of unrelated 
genes is present. Most of all, since GSK3 β is expressed ubiqui- 
tously throughout the heart and regulates many different signaling 
pathways, upstream signaling pathways should be studied further 
in order to understand their contribution to disease development. 
Nevertheless, all in all, these data suggest aberrant Wnt/ β-catenin 
signaling and nuclear plakoglobin translocation as possible causal 
factors for the fibrosis and inflammation seen as part of the ACM 
phenotype ( Fig. 4 ). 
Desmosomal variants and inflammation 
Chelko et al. provided further evidence that inflammatory sig- 
naling pathways play an essential role in the ACM pathophysiol- 
ogy [39] . In the context of inflammation, it is important to clar- 
ify that the immune response present in ACM is made up of two 
components: on one side the infiltration of the myocardium by 
cells of the adaptive immune system, such as lymphocytes and 
macrophages, on the other side the activation of the innate im- 
mune system in cardiac myocytes. The role both components may 
have in the pathogenesis of the disease is still under debate: while 
it is true that a consistent amount of inflammatory cells can be 
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found in the hearts of ACM patients, it is still unclear, whether 
these are a reactive response to myocardial damage or actually the 
promotors of it. On the other hand, the activation of the innate 
component is currently being investigated. In their work the au- 
thors showed that the NF κB signaling pathway is activated in three 
different experimental models of ACM, with different desmosmal 
variants. This pathway is a master regulator of cellular inflamma- 
tory responses, which has clear links to the GSK3 β pathway based 
on evidence indicating that activation of GSK3 β promotes inflam- 
mation through NF κB [40] . More specifically, they used the same 
model of NVRM expressing mutant forms of Jup (JUP2157del2) de- 
scribed by Judge et al. [38] , showing the in vitro activation of 
the NF κB signaling pathway. Furthermore, they also showed how 
the NF κB signaling pathway is activated in Dsg2 mut/mut mice in 
vivo. When comparing cytokine arrays of these mice with WT 
mice, substantial expression of multiple cytokines (IL-1 β , IFN γ , 
TNF α) in the hearts of the Dsg2 mut/mut was shown. The activa- 
tion of the NF κB signaling pathway was further confirmed in iPSC- 
cardiomyocytes from a patient carrying a PKP2 pathogenic variant. 
This suggests an activation of the innate immune system response 
in cardiac myocytes, driven at least in part by NF κB signaling. 
Conclusions 
In ACM, life-threatening ventricular arrhythmias may take place 
mostly in the pre-clinical phase of the disease, before overt struc- 
tural disease can be detected. Further research and insights are 
needed to halt the progression of the disease, especially when 
considering the mechanisms associated with electrical instability. 
Overall, the central role played by PKP2 is confirmed by the fact 
that it is involved in multiple functions, including complex inter- 
actions with other desmosomal proteins. This can in part explain 
the complexity of the phenotype seen upon its deficiency, which 
ranges from a purely electrical disease such as catecholaminergic 
polymorphic VT to an electrical \ structural disease such as Brugada 
Syndrome to a structural disease characterized by mechanical dys- 
function associated with arrhythmias as it is the case in ACM. 
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